Friday, 16 October 2026European Markets

FONCIERE INEA And INTERVEST OFF-WARE Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - fonciere inea (inea.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
fonciere inea (inea.pa) €36.00 7.2% 7.46%
intervest off-ware (into.br) €20.90 4.9% 1.89%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. fonciere inea (inea.pa)

7.2% forward dividend yield and 7.46% return on equity

fonciere inea s.a., a real estate investment company, engages in owning and managing business real estate properties in france. as of december 31, 2010, its property portfolio consisted of 111 buildings. the company was founded in 2005 and is based in paris, france.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.46%.

revenue growth

year-on-year quarterly revenue growth grew by 19.4%, now sitting on 65.15m for the twelve trailing months.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 15, 2023, the estimated forward annual dividend rate is 2.7 and the estimated forward annual dividend yield is 7.2%.

more news about fonciere inea.

2. intervest off-ware (into.br)

4.9% forward dividend yield and 1.89% return on equity

intervest offices & warehouses nv (referred to hereafter as “intervest”) is a public regulated real estate company (rrec) under belgian law, founded in 1996, of which the shares have been listed on euronext brussels (into) since 1999. intervest invests in logistics real estate in belgium and the netherlands and in office buildings in belgium. investments are focused on up-to-date buildings and sustainable (re)development projects, located in strategic locations, with an eye on cluster formation and is aimed at first-rate tenants. the logistics segment of the portfolio in belgium is located on the antwerp - brussels - nivelles, antwerp - limburg - liège, and antwerp - ghent - bruges axes and, in the netherlands, on the moerdijk - 's hertogenbosch - nijmegen, rotterdam - gorinchem - nijmegen and bergen-op-zoom - eindhoven - venlo axes. the office segment of the real estate portfolio focuses on the central cities with an important student population of antwerp, mechelen, brussels and leuven and their surroundings. intervest distinguishes itself in renting space by going beyond merely renting m². the company goes beyond real estate.

earnings per share

as for profitability, intervest off-ware has a trailing twelve months eps of €-0.09.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.89%.

moving average

intervest off-ware's worth is above its 50-day moving average of €20.76 and way higher than its 200-day moving average of €17.41.

more news about intervest off-ware.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com